Zydus and Takeda partner to address emerging infectious diseases

Indian drugmaker Zydus Cadila and Japan’s Takeda Pharmaceutical (TYO: 4502) have entered a partnership to tackle chikungunya, an emerging infectious disease.

Terms of the agreement are not disclosed, but it is expected that this collaboration will boost access to medicines in the future through this novel partnership, the companies stated.

Speaking on this key development, Pankaj Patel, chairman and managing director, of the Zydus group, said: “We have always been committed to working with partners and collaborating to bring affordable therapies and bridge unmet healthcare needs. By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all important step to prevent the disease burden which is highly prevalent in developing countries and causes suffering and disability.”